Robert Abernathy Net Worth

The estimated Net Worth of Robert E Abernathy is at least $25.4 Milion dollars as of 11 August 2020. Mr. Abernathy owns over 4,000 units of Haemonetics stock worth over $872,878 and over the last 21 years he sold HAE stock worth over $24,215,784. In addition, he makes $270,188 as Independent Director at Haemonetics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Abernathy HAE stock SEC Form 4 insiders trading

Robert has made over 27 trades of the Haemonetics stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of HAE stock worth $323,720 on 11 August 2020.

The largest trade he's ever made was selling 122,470 units of Haemonetics stock on 23 April 2012 worth over $9,368,955. On average, Robert trades about 8,490 units every 70 days since 2003. As of 11 August 2020 he still owns at least 12,048 units of Haemonetics stock.

You can see the complete history of Mr. Abernathy stock trades at the bottom of the page.

Robert Abernathy biography

Robert E. Abernathy serves as Independent Director of the Company. Mr. Abernathy served as Chairman and Chief Executive Officer of Halyard Health Inc., a medical technology company and spin-off from Kimberly-Clark, from October 2014 until his retirement in June 2017 (he continued as Chairman until September 2017). Mr. Abernathy joined Kimberly-Clark, a global personal care products company, in 1982 and held numerous roles of increasing responsibility, including President of Kimberly-Clark’s Global Health Care business, Group President, Developing & Emerging Markets, Managing Director, Kimberly-Clark Australia and President, North Atlantic Consumer Products. In addition to his current public company board service, Mr. Abernathy previously served as a director of Halyard Health, Inc. and RadioShack Corp.

What is the salary of Robert Abernathy?

As the Independent Director of Haemonetics, the total compensation of Robert Abernathy at Haemonetics is $270,188. There are 9 executives at Haemonetics getting paid more, with Christopher Simon having the highest compensation of $9,398,200.

How old is Robert Abernathy?

Robert Abernathy is 65, he's been the Independent Director of Haemonetics since 2017. There are 4 older and 7 younger executives at Haemonetics. The oldest executive at Haemonetics Corp. is Richard Meelia, 71, who is the Independent Chairman of the Board.

Insiders trading at Haemonetics

Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy oraz Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.

What does Haemonetics do?

haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right

Complete history of Mr. Abernathy stock trades at Haemonetics, Kimberly-Clark oraz Polished.com Inc

Haemonetics executives and stock owners

Haemonetics executives and other stock owners filed with the SEC include:

• Christopher Simon,
  President, Chief Executive Officer, Director
• William Burke,
  Chief Financial Officer, Executive Vice President
• Michelle Basil,
  Executive Vice President, General Counsel
• Josep Llorens,
  Senior Vice President - Global Manufacturing and Supply Chain
• Jacqueline Scanlan,
  Senior Vice President - Human Resources
• Richard Meelia,
  Independent Chairman of the Board
• Claire Pomeroy,
  Independent Director
• Charles Dockendorff,
  Independent Director
• Catherine Burzik,
  Independent Director
• Robert Abernathy,
  Independent Director
• Ellen Zane,
  Independent Director
• Mark Kroll,
  Independent Director
• Olga Guyette,
  Director – Investor Relations
• Michael Coyle,
  Independent Director
• Anila Lingamneni,
  Executive Vice President, Chief Technology Officer
• Dan Goldstein,
  VP, Corporate Controller
• Susan Bartlett Foote,
  Director
• Ronald G Gelbman,
  Director
• Neil 122 62 507 Ryding,
  EVP, Global Manufacturing
• David Fusco,
  EVP, Global Human Resources
• Brian R Burns,
  EVP, Global QA/RA
• Sandra Jesse,
  VP & CLO
• Ronald Merriman,
  Director
• Susan M Hanlon,
  V.P. Corporate Controller
• Kent J Davies,
  President, Global Markets
• Jonathan White,
  VP Research and Development
• Byron Selman,
  President, Global Markets
• Pedro P Granadillo,
  Director
• Said Bolorforosh,
  EVP, Chief Technology Officer
• William Granville,
  VP, Manufacturing
• Thomas Lawlor,
  President, Patient Division
• Brad Nutter,
  President & CEO
• Yutaka Sakurada,
  President, Japan & Asia
• Alicia R Lopez,
  Senior VP & General Counsel
• Lawrence C Best,
  Director
• Donna C E Williamson,
  Director
• Warren Jr Nighan,
  VP WW Q&ampR Affairs
• Ulrich Eckert,
  President, Europe & Latin Am
• Mikael Gordon,
  President, Haemonetics Europe
• Mark Beucler,
  
• Anthony Pare,
  
• Dave Helsel,
  VP, Global Manufacturing
• Harvey G Klein,
  Director
• Ryoji Sakai,
  President, Japan
• Ronald A Matricaria,
  Director
• Remi Corlin,
  President, Asia
• Mark A Popovsky,
  Vp, Corporate Medical Director
• Ronald J Ryan,
  Senior VP & CFO
• Stephen Swenson,
  VP & General Mgr, Global Plasm
• Peter M Allen,
  President, Donor Division
• Brian Concannon,
  President, Patient Division
• Kathleen Mc Daniel,
  EVP Global Human Resources
• James O'shaughnessy,
  
• Paul Black,
  Director
• Michael I Ruxin,
  VP Global Software Strategies
• Robert B Ebbeling,
  Senior VP, Manufacturing
• Joseph J Forish,
  VP, Human Resources
• Phillip John Brancazio,
  VP, Global Manufacturing
• Michael P Kelly,
  President, NA, Global Plasma
• William Roche Still,
  VP Strategic Mktg, & Bus. Dev.
• Benjamin L Holmes,
  Director
• Keiko Hattori,
  President, Haemonetics Japan
• Jan Conneely,
  VP & GM, Arryx, Inc.
• Christopher J Lindop,
  VP, Finance & CFO
• Laurie A. Miller,
  SVP, Human Resources
• Farris Maryanne Maunsell,
  VP, Chief Accounting Officer
• Lloyd Emerson Johnson,
  Director
• Stewart W Strong,
  President, Global Hospital
• James D Arecca,
  EVP, Chief Financial Officer
• Roy Galvin,
  President, Global Plasma & BC
• Diane M Bryant,
  Director